Literature DB >> 28717438

Emerging potential for bisphosphonates in the treatment of axial spondyloarthritis.

Gianluca Sambataro1, Domenico Sambataro2, Riccardo Polosa2.   

Abstract

Entities:  

Year:  2017        PMID： 28717438      PMCID： PMC5502955          DOI： 10.1177/2040622317702363

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


× No keyword cloud information.
  11 in total

Review 1.  Imaging in Spondyloarthritis: Controversies in Recognition of Early Disease.

Authors:  Ulrich Weber; Anne Grethe Jurik; Robert G W Lambert; Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2016-09       Impact factor: 4.592

2.  Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial.

Authors:  C C Mok; O C Li; K L Chan; L Y Ho; P K Hui
Journal:  Scand J Rheumatol       Date:  2015-08-14       Impact factor: 3.641

3.  Classification criteria for spondyloarthropathies.

Authors:  Ozgur Akgul; Salih Ozgocmen
Journal:  World J Orthop       Date:  2011-12-18

4.  Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study.

Authors:  Sofia Ramiro; Carmen Stolwijk; Astrid van Tubergen; Désirée van der Heijde; Maxime Dougados; Filip van den Bosch; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2013-08-16       Impact factor: 19.103

Review 5.  Bisphosphonates: focus on inflammation and bone loss.

Authors:  Tommaso Iannitti; Stefano Rosini; Daniele Lodi; Bruno Frediani; Valentina Rottigni; Beniamino Palmieri
Journal:  Am J Ther       Date:  2012-05       Impact factor: 2.688

6.  Zoledronic acid inhibits human osteoblast activities.

Authors:  Fernanda G Basso; Ana Paula Silveira Turrioni; Josimeri Hebling; Carlos A de Souza Costa
Journal:  Gerontology       Date:  2013-07-18       Impact factor: 5.140

7.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

8.  Bisphosphonates vs infliximab in ankylosing spondylitis treatment.

Authors:  Ombretta Viapiana; Davide Gatti; Luca Idolazzi; Elena Fracassi; Silvano Adami; Sonila Troplini; Maria Rosaria Povino; Maurizio Rossini
Journal:  Rheumatology (Oxford)       Date:  2013-09-24       Impact factor: 7.580

Review 9.  Bisphosphonates: mechanism of action and role in clinical practice.

Authors:  Matthew T Drake; Bart L Clarke; Suneep Khosla
Journal:  Mayo Clin Proc       Date:  2008-09       Impact factor: 7.616

10.  Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study.

Authors:  Runsheng Wang; Sherine E Gabriel; Michael M Ward
Journal:  Arthritis Rheumatol       Date:  2016-06       Impact factor: 10.995
View more
  1 in total

Review 1.  Bone phenotypes in rheumatology - there is more to bone than just bone.

Authors:  Christian S Thudium; Signe Holm Nielsen; Samra Sardar; Ali Mobasheri; Willem Evert van Spil; Rik Lories; Kim Henriksen; Anne-Christine Bay-Jensen; Morten A Karsdal
Journal:  BMC Musculoskelet Disord       Date:  2020-11-28       Impact factor: 2.362
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.